



(43) International Publication Date  
28 September 2017 (28.09.2017)

- (51) International Patent Classification:  
A61K 41/00 (2006.01) A61K 31/11 (2006.01)
- (21) International Application Number:  
PCT/US2017/023844
- (22) International Filing Date:  
23 March 2017 (23.03.2017)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
62/312,988 24 March 2016 (24.03.2016) US
- (71) Applicant: **DIFFUSION PHARMACEUTICALS LLC**  
[US/US]; 2020 Avon Court, Suite 4, Charlottesville, Virginia 22902 (US).
- (72) Inventor: **GAINER, John L.**; c/o Diffusion Pharmaceuticals LLC, 2020 Avon Court, Suite 4, Charlottesville, Virginia 22902 (US).
- (74) Agent: **TSIMARAS, Michael**; Hoxie & Associates LLC, 75 Main Street, Suite 203, Millburn, New Jersey 07041 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))



**WO 2017/165667 A1**

(54) Title: USE OF BIPOLAR TRANS CAROTENOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR TREATMENT OF CANCER

(57) Abstract: The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.

## USE OF BIPOLAR TRANS CAROTENOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR TREATMENT OF CANCER

### Cross-Reference to Related Applications

**[001]** This application claims priority to United States Provisional Application No. 62/312,988, filed March 24, 2016, the contents of which are incorporated by reference in their entirety.

**[002]** The subject disclosure relates to the use of bipolar trans carotenoids with chemotherapy and/or radiotherapy for the treatment of cancer including brain and pancreatic cancer.

### Background

**[003]** Getting an adequate supply of oxygen to the tissues in our body begins in the lungs, where gas exchange occurs and oxygen enters the bloodstream while carbon dioxide exits the bloodstream to be exhaled. The process of gas exchange occurs via diffusion, which is the movement of molecules from an area of high concentration to an area of low concentration. Once the oxygen enters into the bloodstream it must diffuse through the plasma and then enter red blood cells where it binds to hemoglobin. The oxygen is then transported through the bloodstream, and as it enters areas of the body with low oxygen concentration, the oxygen is off-loaded by the red blood cells so that it can again diffuse through the blood plasma and capillary walls to enter tissues. The oxygen then enters the mitochondria where it is utilized for metabolic purposes.

**[004]** Each of the steps described above for the movement of oxygen through the body results in some form of resistance, with diffusion through the plasma being a de facto “rate-limiting” step in the movement of oxygen through the body, accounting for 70-90% of the overall resistance. Thus, if the movement of oxygen through plasma could be increased, it would be possible to increase the amount of oxygen that can make its way through the pathway at any given time and into the various tissues in the body, including hypoxic tissues such as tumors.

**[005]** The process of diffusion follows Fick's law, which states that the rate of oxygen diffusion through plasma is dependent upon 1) the plasma thickness; 2) the concentration gradient of oxygen; and 3) a proportionality constant known as the diffusion coefficient (also known as diffusivity). Thus, those are the three factors that could potentially be altered in order to increase the diffusion of oxygen.

**[006]** The plasma thickness is set by arterial anatomy, and thus is not readily altered. The concentration gradient of oxygen can be altered by increasing the percentage of oxygen that a patient breathes (air is 21% oxygen) or through the addition of hemoglobin-like molecules into the bloodstream.

**[007]** It is believed that trans sodium crocetin (TSC) and other bipolar trans carotenoids alter the molecular arrangement of water molecules in the plasma (which is composed of 90% water), with the altered structure being less dense than untreated plasma. Water is composed of two hydrogen atoms and one oxygen atom, with a net positive charge found on the hydrogen atoms and a net negative charge found on the oxygen atom. This results in the formation of hydrogen bonds, which are simply an attraction between the net-negatively charged oxygen of one water molecule and the net-positively charged hydrogen atoms of another water molecule. Theoretically, one water molecule can form four hydrogen bonds with neighboring water molecules. However, the literature indicates that a water molecule actually forms, on average, 2 to 3.6 hydrogen bonds.

## **Tumor Hypoxia**

**[008]** Hypoxia is a deficiency in a sufficient supply of oxygen. It has been known for well over 50 years that tumors are specifically susceptible to developing hypoxia, which is driven by a combination of rapid growth, structural abnormalities of the tumor microvessels, and disturbed circulation within the tumor. There are a number of consequences to tumor hypoxia, including:

- Increased resistance to ionizing radiation
- A more clinically aggressive phenotype
- An increased potential for more invasive growth
- Increased regional and distal tumor spreading

## **Trans Sodium Crocetinate Increases Oxygenation of Hypoxic Tumors**

**[0009]** While first studied for the treatment of hemorrhagic shock and ischemia, the use of TSC as an agent to increase the oxygenation of tumors has also been studied. Tumor hypoxia is a leading cause of resistance to both radiation and chemotherapy in a number of solid tumors.

## **Glioblastoma Multiforme**

**[0010]** Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous cell population with a number of negative attributes. GBM cells are typically genetically unstable (thus prone to mutation), highly infiltrative, angiogenic, and resistant to chemotherapy. The mutations typically found in GBM allow the tumor to grow and thrive in a hypoxic environment. Both activating mutations and loss of tumor suppressor genes give rise to the highly complex and difficult to treat nature of the disease. For example, approximately 50% of GBM tumors have amplification of the epidermal growth factor receptor (EGFR), which can then induce activation of the PI3K signaling pathway.

**[0011]** GBM is classified into two major subclasses (primary or secondary) depending upon the clinical properties as well as the chromosomal and genetic alterations that are unique to each class. Primary GBM arises de novo from normal glial cells and typically occurs in those over the age of 40, while secondary GBM arises from transformation of lower grade tumors and is usually seen in younger patients). Primary GBM is believed to account for approximately 95% of all GBMs.

**[0012]** While GBM is the most common form of primary brain tumor involving glial cells, it is still relatively rare as approximately 24,000 people in the United States were diagnosed with some form of malignant brain cancer in 2014. Gliomas account for approximately 80% of malignant brain cancers, with GBM accounting for approximately 45% of gliomas. The median age of GBM diagnosis is approximately 65 years, with the incidence of GBM in those over 65 increasing rapidly as shown by a doubling in incidence from 5.1 per 100,000 in the 1970's to 10.6 per 100,000 in the 1990's. Those diagnosed with the disease have a very grim prognosis, with the median survival time of untreated patients being only 4.5

months. Current standard of care treatment only provides 12-14 months of survival time after diagnosis.

### **Current Treatments for GBM**

**[0013]** Standard of care for GBM tumors always begins with surgical resection of the tumor, unless the tumor is deemed inoperable due to its location near vital centers of the brain. This is performed both to alleviate the symptoms associated with the disease as well as to facilitate treatment of any residual tumor cells. Even with advances in surgical technique, complete removal of the tumor with clean margins is almost never possible, as the tumors are highly infiltrative and typically extend into the normal brain parenchyma. Due to this, almost all GBM patients have recurrence of the tumor, with 90% occurring at the primary site.

**[0014]** Due to the invasive nature of the tumors, surgical resection is followed by radiotherapy coupled with the use of chemotherapeutic agents. Radiotherapy involves the administration of irradiation to the whole brain. While nitrosoureas were the most common chemotherapeutic agents used for a number of decades, in 1999 temozolomide (TMZ) became available and is now a part of the standard of care. This is due to a clinical trial that showed the addition of TMZ to surgery and radiation increased median survival in newly diagnosed GBM patients to 14.6 months compared to 12.1 months for the surgery and radiation only group.

**[0015]** Most chemotherapeutic drugs have a limited ability to cross the blood brain barrier (BBB), thus a strategy to circumvent this was the development of dissolvable chemotherapy wafers (Gliadel®) that could be placed in the tumor bed following surgical resection. Gliadel® contains the nitrosourea chemotherapeutic agent carmustine that is released for several weeks, in contrast to systemically administered carmustine that has a very short half-life. While Gliadel® wafers were shown to be safe, the drugs' addition to radiation and TMZ did not result in a statistically significant increase in survival.

**[0016]** GBM tumors show increased expression of VEGF, and bevacizumab has been approved by the FDA for the treatment of recurrent GBM. A Phase 2 study found that bevacizumab treatment in patients with recurrent GBM increased six-month progression-free survival from a historical 9-15% to 25% with overall six-month survival of 54%. Another Phase

2 study showed that recurrent GBM patients treated with bevacizumab at a lower dose but a higher frequency had even higher six-month progression-free survival of 42.6%.

**[0017]** While bevacizumab has shown success in recurrent GBM, it is not utilized in newly diagnosed patients as two separate clinical trials showed no difference in overall survival in patients treated with radiation, TMZ, and bevacizumab compared to patients treated with only radiation and TMZ. Bevacizumab treatment did result in an increase in progression free survival in both studies; however, why the effect in progression free survival did not translate to an increase in overall survival is unclear. In addition, it was reported that patients treated with bevacizumab had an increased symptom burden, a worse quality of life, and a decline in neurocognitive function.

### **Pancreatic Cancer**

**[0018]** It is estimated that in 2016 approximately 49,000 people will be diagnosed with pancreatic cancer in the United States. More than half of these patients will be diagnosed with metastatic disease. The five-year survival rates for patients with pancreatic cancer are dismal (<14%) and are particularly bad for those with metastatic disease (~1%).

**[0019]** Pancreatic cancer is responsible for 7% of all cancer deaths in both men and women, making it the fourth leading cause of cancer death in the U.S. Estimates indicate that 40% of pancreatic cancer cases are sporadic in nature, 30% are related to smoking, 20% may be associated with dietary factors, with only 5-10% hereditary.

**[0020]** Pancreatic cancer is difficult to diagnose in early stages. The reason for this is because initial symptoms of the disease are often nonspecific and subtle in nature, and include anorexia, malaise, nausea, fatigue, and back pain. Approximately 75% of all pancreatic carcinomas occur within the head or neck of the pancreas, 15-20% occur in the body of the pancreas, and 5-10% occur in the tail.

**[0021]** The only potential curative therapy for pancreatic cancer is complete surgical resection. Unfortunately, this is only possible for approximately 20% of cases, and even of those patients whose cancer is surgically resected, 80% will develop metastatic disease within two to three years following surgery. Patients with unresectable pancreatic cancer have a median overall survival of 10 to 14 months while patients diagnosed with Stage IV disease (indicative of metastases) have a 5-year overall survival of just 1%.

[0022] Pancreatic cancers are highly hypoxic as shown by the results of multiple studies. A study reporting the direct measurement of oxygenation in human pancreatic tumors prior to surgery showed dramatic differences between tumors and normal tissue. The partial pressure of oxygen (pO<sub>2</sub>) ranged between 0-5.3 mmHg in tumors but in adjacent normal tissue it ranged from 9.3-92.7 mmHg. Hypoxic areas are also frequently found when examining tissue from mouse models of pancreatic cancer.

[0023] The exocrine cells and endocrine cells of the pancreas form different types of tumors. It's very important to distinguish between exocrine and endocrine cancers of the pancreas. They have distinct risk factors and causes, have different signs and symptoms, are diagnosed using different tests, are treated in different ways, and have different outlooks.

### **Exocrine tumors**

[0024] Exocrine tumors are by far the most common type of pancreas cancer. When someone says that they have pancreatic cancer, they usually mean an exocrine pancreatic cancer.

### **Pancreatic adenocarcinoma**

[0025] An adenocarcinoma is a cancer that starts in gland cells. About 95% of cancers of the exocrine pancreas are adenocarcinomas. These cancers usually begin in the ducts of the pancreas. But sometimes they develop from the cells that make the pancreatic enzymes, in which case they are called *acinar cell carcinomas*.

### **Less common types of cancers**

[0026] Other cancers of the exocrine pancreas include adenosquamous carcinomas, squamous cell carcinomas, signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with giant cells. These types are distinguished from one another based on how they look under the microscope.

**Solid pseudopapillary neoplasms (SPNs)**

[0027] These are rare, slow-growing tumors that almost always occur in young women. Even though these tumors tend to grow slowly, they can sometimes spread to other parts of the body, so they are best treated with surgery. The outlook for people with these tumors is usually very good.

**Ampullary cancer (carcinoma of the ampulla of Vater)**

[0028] This cancer starts in the ampulla of Vater, which is where the bile duct and pancreatic duct come together and empty into the small intestine. Ampullary cancers aren't technically pancreatic cancers, but they are included in this document because their treatments are very similar.

[0029] Ampullary cancers often block the bile duct while they are still small and have not spread far. This blockage causes bile to build up in the body, which leads to yellowing of the skin and eyes (jaundice) and can turn urine dark. Because of this, these cancers are usually found at an earlier stage than most pancreatic cancers, and they usually have a better prognosis (outlook) than typical pancreatic cancers.

**Endocrine tumors**

[0030] Tumors of the endocrine pancreas are uncommon, making up less than 4% of all pancreatic cancers. As a group, they are sometimes known as pancreatic neuroendocrine tumors (NETs) or islet cell tumors.

[0031] Pancreatic NETs can be benign or malignant (cancer). Benign and malignant tumors can look alike under a microscope, so it isn't always clear whether or not a pancreatic NET is cancer. Sometimes the diagnosis only becomes clear when the tumor spreads outside of the pancreas. There are many types of pancreatic NETs.

**Functioning tumors**

[0032] About half of pancreatic NETs make hormones that are released into the blood and cause symptoms. These are called *functioning* tumors. Each one is named for the type of hormone-making cell it starts in.

- **Gastrinomas** come from cells that make gastrin. About half of gastrinomas are cancers.
- **Insulinomas** come from cells that make insulin. Most insulinomas are benign (not cancers).
- **Glucagonomas** come from cells that make glucagon. Most glucagonomas are cancers.
- **Somatostatinomas** come from cells that make somatostatin. Most somatostatinomas are cancers.
- **VIPomas** come from cells that make vasoactive intestinal peptide (VIP). Most VIPomas are cancers.
- **PPomas** come from cells that make pancreatic polypeptide. Most PPomas are cancers.

[0033] The most common types of functioning NETs are gastrinomas and insulinomas. The other types occur very rarely.

### **Non-functioning tumors**

[0034] These tumors don't make enough excess hormones to cause symptoms. They are more likely to be cancer than functioning tumors. Because they don't make excess hormones that cause symptoms, they can often grow quite large before they are found.

### **Carcinoid tumors**

[0035] These are another type of NET that rarely can start in the pancreas, although they are much more common in other parts of the digestive system. These tumors often make serotonin (also called 5-HT) or its precursor, 5-HTP.

[0036] The treatment and outlook for pancreatic NETs depend on the specific tumor type and the stage (extent) of the tumor, but the outlook is generally better than that of pancreatic exocrine cancers.

### **Current Treatment Options for Pancreatic Cancer**

**[0037]** Surgery remains the primary mode of treatment for patients with pancreatic cancer. However, there is an important role for chemotherapy and/or radiation in an adjuvant (given to prevent recurrence) or neoadjuvant (given before surgery to shrink the tumor to make complete resection more probable) setting as well as in patients with unresectable disease.

**[0038]** Since its approval in 1996, gemcitabine has been partnered with approximately 30 different agents in late-stage clinical trials in an attempt to improve upon the effectiveness of gemcitabine alone in treating patients with metastatic pancreatic cancer. Only two of these trials have led to an FDA approval – erlotinib (Tarceva®) and nab-paclitaxel (Abraxane®).

**[0039]** In patients with metastatic disease, the use of erlotinib with gemcitabine led to a significantly higher one-year survival rate than with the use of gemcitabine alone (23% vs. 17%,  $P = 0.023$ ) as well as an increased median overall survival (6.24 months vs. 5.91 months,  $P = 0.038$ ). A more recent study showed that the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine significantly improved overall survival in treatment naïve patients with metastatic cancer, as overall survival was approximately two months longer in patients treated with combination therapy (8.5 vs. 6.7 months).

**[0040]** The Folfirinox (leucovorin + 5-fluorouracil + oxaliplatin + irinotecan) regimen was shown to significantly improve overall survival compared to treatment with gemcitabine (11.1 months vs. 6.8 months). While dramatically improving overall survival, the Folfirinox treatment was accompanied by serious adverse events and thus is only recommended for patients with good performance status.

**[0041]** Other combinations of gemcitabine with cisplatin, oxaliplatin, irinotecan, or docetaxel tested in Phase 3 trials have not been of superior benefit to gemcitabine alone. The combination therapy nab-paclitaxel and gemcitabine was recently approved by the FDA as an additional standard of care for the treatment of patients with untreated pancreatic adenocarcinoma. However, the improvements were modest, and treatment of pancreatic cancer remains an intense area of research, with 92 products in all stages of clinical development with 14 of them in Phase 3 at this time according to [clinicaltrials.gov](http://clinicaltrials.gov).

**[0042]** Just recently, the FDA approved Onivyde® (irinotecan liposome injection) in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer

who were previously treated with gemcitabine-based chemotherapy. In the pivotal clinical trial, patients treated with Onivyde<sup>®</sup> plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin.

### **Brain Metastases**

**[0043]** In contrast to the relative rarity of primary brain cancers, life-threatening cancers that metastasize to the brain are much more common and represent a serious complication in the treatment of many cancer types. Up to 30% of adult cancer patients will suffer from brain metastases. There are approximately 170,000 cases of metastatic brain cancer every year in the United States. Incidence of brain metastases varies depending upon the primary tumor type, although lung cancer appears to carry the greatest risk. The prognosis for patients with brain metastases is very grim, with current treatment options only resulting in median overall survival times of less than one year.

**[0044]** Treatment for brain metastases involves both controlling the symptoms associated with the condition as well as attacking cancer directly. Brain metastases typically result in edema that can be controlled with the use of steroids; however, long-term use of steroids typically results in side effects that greatly diminishes a patient's quality of life. Approximately 25-45% of patients will experience seizures and require the use anti-epileptic drugs. Surgery is only utilized in patients with a solitary brain metastatic lesion. Radiation therapy remains the standard of care for the vast majority of patients with brain metastases. There is very limited evidence for the use of chemotherapy, as few clinical trials have been conducted. There are no medications approved for the treatment of brain metastases.

### **Chemotherapy**

**[0045]** Chemotherapy drugs can be grouped by how they work, their chemical structure, and their relationships to other drugs. Some drugs work in more than one way, and may belong to more than one group. Knowing how the drug works is important in predicting side effects from it. This helps doctors decide which drugs are likely to work well together. If more than one drug will be used, this information also helps them plan exactly when each of the drugs should be given (in which order and how often).

**Alkylating agents**

[0046] Alkylating agents keep the cell from reproducing by damaging its DNA. These drugs work in all phases of the cell cycle and are used to treat many different cancers, including cancers of the lung, breast, and ovary as well as leukemia, lymphoma, Hodgkin disease, multiple myeloma, and sarcoma.

[0047] Because these drugs damage DNA, they can affect the cells of the bone marrow which make new blood cells. In rare cases, this can lead to leukemia. The risk of leukemia from alkylating agents is “dose-dependent,” meaning that the risk is small with lower doses, but goes up as the total amount of the drug used gets higher. The risk of leukemia after getting alkylating agents is highest about 5 to 10 years after treatment.

**Antimetabolites**

[0048] Antimetabolites interfere with DNA and RNA growth by substituting for the normal building blocks of RNA and DNA. These agents damage cells during the phase when the cell’s chromosomes are being copied. They are commonly used to treat leukemias, cancers of the breast, ovary, and the intestinal tract, as well as other types of cancer.

**Anti-tumor antibiotics**

[0049] These drugs are not like the antibiotics used to treat infections. They work by changing the DNA inside cancer cells to keep them from growing and multiplying.

**Topoisomerase inhibitors**

[0050] These drugs interfere with enzymes called topoisomerases, which help separate the strands of DNA so they can be copied. (Enzymes are proteins that cause chemical reactions

in living cells.) Topoisomerase inhibitors are used to treat certain leukemias, as well as lung, ovarian, gastrointestinal, and other cancers.

[0051] Topoisomerase II inhibitors can increase the risk of a second cancer – acute myelogenous leukemia (AML) – as early as 2 to 3 years after the drug is given.

### **Mitotic inhibitors**

[0052] *Mitotic inhibitors* are compounds derived from natural products, such as plants. They work by stopping cells from dividing to form new cells but can damage cells in all phases by keeping enzymes from making proteins needed for cell reproduction. They are used to treat many different types of cancer including breast, lung, myelomas, lymphomas, and leukemias. These drugs may cause nerve damage, which can limit the amount that can be given.

### **Other chemotherapy drugs**

[0053] Some chemotherapy drugs act in slightly different ways and do not fit well into any of the other categories. Examples include drugs like L-asparaginase, which is an enzyme, and the proteasome inhibitor bortezomib (Velcade®).

[0054] US Patent 8,030,350 discloses the use of bipolar trans carotenoids along with chemotherapy and radiation therapy for the treatment of cancer.

### **Summary**

[0055] In one embodiment, the disclosure includes a method of **treating cancer (solid tumor) in a mammal** (e.g. human) comprising

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:

YZ-TCRO-ZY

where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

- b) **administering to the mammal radiation therapy**, wherein said bipolar trans carotenoid salt is administered at time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.

**[0056]** In a preferred embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.15-0.35 mg/kg 45-60 minutes prior to administration of said radiation therapy. In some embodiments, the subject mammal is also administered chemotherapy in addition to the radiation therapy, e.g. administering temozolomide 7 times per week for 6 weeks.

**[0057]** A still further embodiment of the disclosure relates to a method of **treating cancer (solid tumor) in a mammal** (e.g. human) comprising

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:

$$YZ\text{-TCRO-ZY}$$

where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

- b) **administering chemotherapy to the mammal**, wherein said bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said chemotherapy.

[0058] In a preferred embodiment, TSC administered at a dose of 0.75 – 2.0 mg/kg 1-2 hour prior to administration of said chemotherapy.

[0059] The cancer is selected from the group consisting of squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer, urological and male genital cancer, bladder cancer, prostate cancer, bone cancer, cancers of the endocrine glands (e.g. pancreatic cancer), cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer. The chemotherapy is selected from the group consisting of alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, and anti-microtubule agents. In some embodiments, the subject mammal is also administered radiation therapy in addition to the chemotherapy.

[0060] In an advantageous embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.75 - 2.0 mg/kg, 1-2 hrs. prior to administration of said chemotherapy. The chemotherapy is one or more compounds selected from the group consisting of gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.

[0061] In one embodiment, the method is administering 1.5 mg/kg TSC 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.

[0062] In another embodiment, 1.5 mg/kg TSC is administered 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.

[0063] In another embodiment, the subject disclosure relates to a method of treating a **cancer of the pancreas** in a mammal (e.g. human) comprising:

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, and

- b) **administering to the mammal chemotherapy**, wherein the bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of the chemotherapy.

**[0064]** In an advantageous embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.75 - 2.0 mg/kg, 1-2 hrs. prior to administration of said chemotherapy. The chemotherapy is one or more compounds selected from the group consisting of gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.

**[0065]** In one embodiment, the method is administering 1.5 mg/kg TSC 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.

**[0066]** In another embodiment, 1.5 mg/kg TSC is administered 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.

**[0067]** The disclosure also relates to a method of treating a **cancer of the brain (e.g. glioblastoma) in a mammal** (e.g. human) comprising:

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:

YZ-TCRO-ZY

where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant

groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, and

- b) **administering radiation therapy to the mammal** wherein the bipolar trans carotenoid salt is administered at time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.

**[0068]** When the bipolar trans carotenoid is TSC, it is administered at a dose of 0.15 – 0.35 mg/kg 45-60 minutes prior to said administration, typically external beam radiation therapy. In one embodiment, the radiation therapy is administering 5 times per week for 6 weeks. In another embodiment, the method includes administering chemotherapy to the mammal, e.g. administering temozolomide 7 times per week for 6 weeks.

**[0069]** In all of the above embodiments, advantageously the bipolar trans carotenoid salt is TSC is in the form of a composition with a cyclodextrin.

### **Brief Description of the Figures**

**[0070]** Certain aspects of the disclosure will be apparent with regard to the following figures.

**[0071]** Figure 1 illustrates the change in partial pressure of oxygen of a hyperoxic rat resulting from administration of a low efficacious dose amount compared to a high efficacious dose amount of TSC.

**[0072]** Figure 2 illustrates the observed effect that a combination therapy of TSC and cisplatin had on tumor volume, which is discussed in Example 1.

**[0073]** Figure 3 illustrates the observed effect that a combination therapy of TSC and gemcitabine (10 mg/kg) had on tumor volume, which is discussed in Example 2.

**[0074]** Figure 4 illustrates the observed effect that a combination therapy of TSC and gemcitabine (5 mg/kg) had on tumor volume, which is discussed in Example 2.

**[0075]** Figure 5 illustrates the observed effect that a combination therapy of TSC and gemcitabine (7.5 mg/kg) had on tumor volume, which is discussed in Example 2.

**[0076]** Figure 6 illustrates the observed effect that a combination therapy of TSC and temozolomide had on tumor volume, which is discussed in Example 3.

[0077] Figure 7 illustrates the observed effect that a combination therapy of TSC and doxorubicin had on tumor volume, which is discussed in Example 4.

[0078] Figure 8 illustrates the observed effect that a combination therapy of TSC and paclitaxel had on tumor volume, which is discussed in Example 5.

[0079] Figure 9 illustrates the observed tumor area changes in tumor-bearing patients treated with TSC in combination with the standard of care treatment for glioblastoma multiforme (shown as median tumor volume of all patients).

[0080] Figure 10 illustrates the patient distribution of tumor reduction in patients treated with TSC in combination with the standard of care treatment for glioblastoma multiforme.

### **Detailed Description**

[0081] The subject disclosure relates to compounds and compositions including chemotherapy agents and bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.

It is well established that tumors are hypoxic with many tumor types being highly hypoxic. See Table 1 below:

Table 1: Oxygenation of tumors and the surrounding normal tissue (aggregated from multiple studies)

Tumor Type	Median Tumor pO <sub>2</sub> * (number of patients)	Median Normal pO <sub>2</sub> * (number of patients)
Glioblastoma	4.9 (10)	ND
	5.6 (14)	ND
Head and Neck Carcinoma	12.2 (30)	40.0 (14)
	14.7 (23)	43.8 (30)
	14.6 (65)	51.2 (65)
Lung Cancer	7.5 (17)	38.5 (17)
Breast Cancer	10.0 (15)	ND
Pancreatic Cancer	2.7 (7)	51.6 (7)
Cervical Cancer	5.0 (8)	51 (8)

	5.0 (74)	ND
	3.0 (86)	ND
Prostate Cancer	2.4 (59)	30.0 (59)
Soft Tissue Sarcoma	6.2 (34)	ND5
	18 (22)	ND

\* pO<sub>2</sub> measured in mmHg. Measurements were made using a commercially available oxygen electrode (the ‘Eppendorf’ electrode). The values shown are the median of the median values for each patient. ND, not determined; pO<sub>2</sub>, oxygen partial pressure. Brown, JM and Wilson, WR. “Exploiting tumour hypoxia in cancer treatment.” *Nat. Rev. Cancer* 4(6) 2004: 437-447.

**[0082]** Further, it is known that hypoxic tumors are more resistant to radiotherapy and chemotherapy.

**[0083]** It has been discovered that for a mammal, there are two concentrations of a bipolar trans carotenoid, such as TSC, that result in increased oxygen partial pressure—the “low” dose and the “high” dose--in a tumor. For humans, the low dose range is 0.15- 0.35 mg/kg and the high dose range is 0.75 to 2.0 mg/kg. Both doses result in approximately the same maximum increase in oxygen partial pressure. Importantly, the high dose results in a sustained maximum oxygen partial pressure while the low dose does not. An example of this phenomenon is shown in FIG. 1

**[0084]** The methods of the subject disclosure are directed to administering a dose of a bipolar trans carotenoid at a dose and at the proper time prior to administration of chemotherapy or radiation therapy such that the oxygen partial pressure is elevated inside the tumor while the chemotherapy or radiation therapy is administered so as to obtain increased killing effect of the chemotherapy and or radiotherapy on the cancer cells/tumor.

**[0085]** In one embodiment, provided is a method (Method A) of treating cancer in a mammal (e.g. human) comprising

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

b) administering to the mammal radiation therapy, wherein said bipolar trans carotenoid salt is administered at time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.

**[0086]** Further provided is Method A as follows:

- A.1 Method A, wherein the bipolar trans carotenoid is TSC.
- A.2 Method A or A.1, wherein the bipolar trans carotenoid is administered at a dose of 0.05-0.5 mg/kg.
- A.3 Method A or A.1-A.2, wherein the bipolar trans carotenoid is administered at a dose of 0.15-0.35 mg/kg.
- A.4 Method A or A.1-A.3, wherein the bipolar trans carotenoid is administered at a dose of 0.25 mg/kg.
- A.5 Method A or A.1-A.4, wherein the bipolar trans carotenoid is administered 30-120 minutes prior to administration of said radiation therapy.
- A.6 Method A or A.1-A.5, wherein the bipolar trans carotenoid is administered 45-60 minutes prior to administration of said radiation therapy.
- A.7 Method A of A.1-A.6, wherein the bipolar trans carotenoid is administered 2-5 times per week.
- A.8 Method A of A.1-A.7, wherein the bipolar trans carotenoid is administered 3 times per week.
- A.9 Method A or A.1-A.8, wherein said radiation therapy is external beam radiation therapy (e.g., three-dimensional conformal radiation therapy, intensity modulated radiation therapy, proton beam therapy, stereotactic radiation therapy).

- A.10 Method A or A.1-A.8, wherein said radiation therapy is internal beam radiation therapy.
- A.11 Method A or A.1-A.10, wherein said radiation therapy is administered in an amount between 0.1 Gy and 5 Gy per radiation therapy session.
- A.12 Method A or A.1-A.11, wherein said radiation therapy is administered in an amount of 2 Gy per radiation therapy session.
- A.13 Method A or A.1-A.12, wherein said radiation therapy is administered 5 times per week for 6 weeks.
- A.14 Method A or A.1-A.13, further comprising administering chemotherapy to said mammal.
- A.15 Method A.14, wherein the chemotherapy is administered at least once a week for at least three weeks.
- A.16 Method A.14 or A.15, wherein the chemotherapy is administered 7 times a week for 6 weeks.
- A.17 Any of Methods A.14-A.16, wherein said chemotherapy is selected from the group consisting of alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, and anti-microtubule agents.
- A.18 Any of Methods A.14-A.17, wherein said chemotherapy is one or more compounds selected from the group consisting of temozolomide, gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.
- A.19 Any of Methods A.14-A.18, wherein said chemotherapy is one or more compounds selected from temozolomide, gemcitabine, irinotecan, and celecoxib.
- A.20 Any of Methods A.14-A.19, wherein said chemotherapy is one or both of gemcitabine and nab-paclitaxel.
- A.21 Any of Methods A.14-A.20, wherein said chemotherapy is gemcitabine.
- A.22 Any of Methods A.14-A.21, wherein said chemotherapy is temozolomide.

- A.23 Any of Methods A.14-A.22 or A.22, wherein said administering chemotherapy comprises administering temozolomide 7 times per week for 6 weeks.
- A.24 Any of Methods A.14-A.23, wherein said chemotherapy is administered after said radiation therapy.
- A.25 Any of Methods A.14-A.24, wherein said bipolar trans carotenoid salt is administered with chemotherapy at a dose of 1.5 mg/kg.
- A.26 Method A or A.1-A.25, wherein said cancer is brain cancer.
- A.27 Method A or A.1-A.26, wherein said brain cancer is a glioblastoma multiforme.
- A.28 Method A or A.1-A.27, wherein the bipolar trans carotenoid salt is TSC is in the form of a composition with a cyclodextrin.
- A.29 Method A or A.1-A.28, wherein the bipolar trans carotenoid salt is TSC is in the form of a lyophilized composition with a cyclodextrin.
- A.30 Method A or A.1-A.29, wherein the bipolar trans carotenoid is synthetic TSC.
- A.31 Method A or A.1-A.30, wherein the absorbency of the bipolar trans carotenoid salt (i.e., TSC) at a highest peak occurring in the visible light wavelength range (i.e., between 380 to 470 nm) divided by the absorbency of a peak occurring in the ultraviolet wavelength range (i.e., between 220 to 300 nm) is greater than 7, greater than 7.5, greater than 8.0, or greater than 8.5.
- A.32 Method A.31, wherein the quotient obtained is between 7.5 and 9.0.
- A.33 Method A.32, wherein the quotient obtained is between 8.0 and 8.8.

**[0087]** In another embodiment, provided is a method (Method B) of treating cancer in a mammal (e.g. human) comprising

- a) administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

- b) administering chemotherapy to the mammal, wherein said bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said chemotherapy.

**[0088]** Further provided is Method B as follows:

- B.1 Method B, wherein the bipolar trans carotenoid is TSC.
- B.2 Method B or B.1, wherein said bipolar trans carotenoid is administered at a dose of 0.6-2.5 mg/kg.
- B.3 Method B or B.1-B.2, wherein said bipolar trans carotenoid is administered at a dose of 0.75-2.0 mg/kg.
- B.4 Method B or B.1-B.3, wherein said bipolar trans carotenoid is administered at a dose of 1.5 mg/kg.
- B.5 Method B or B.1-B.4, wherein the bipolar trans carotenoid is administered 30-120 minutes prior to administration of said chemotherapy.
- B.6 Method B or B.1-B.5, wherein the bipolar trans carotenoid is administered 45-60 minutes prior to administration of said chemotherapy.
- B.7 Method B or B.1-B.6, wherein the bipolar trans carotenoid is administered once per week.
- B.8 Method B or B.1-B.7, wherein the bipolar trans carotenoid is administered once per week for 3 weeks.
- B.9 Method B or B.1-B.8, wherein the chemotherapy is administered at least once a week for at least three weeks.
- B.10 Method B or B.1-B.9, wherein the chemotherapy is administered 7 times a week for 6 weeks.

- B.11 Method B or B.1-B.10, wherein said chemotherapy is selected from the group consisting of alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, and anti-microtubule agents.
- B.12 Method B or B.1-B.11, wherein said chemotherapy is one or more compounds selected from the group consisting of temozolomide, gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.
- B.13 Method B or B.1-B.12, wherein said chemotherapy is one or more compounds selected from temozolomide, gemcitabine, irinotecan, and celecoxib.
- B.14 Method B or B.1-B.13, wherein said chemotherapy is one or both of gemcitabine and nab-paclitaxel.
- B.15 Method B or B.1-B.14, wherein said chemotherapy is gemcitabine.
- B.16 Method B or B.1-B.15, wherein said chemotherapy is temozolomide.
- B.17 Method B or B.1-B.16, wherein said administering chemotherapy comprises administering temozolomide 7 times per week for 6 weeks.
- B.18 Method B or B.1-B.17, wherein administering said bipolar trans carotenoid is administering 1.5 mg/kg TSC 45-60 minutes prior administering said chemotherapy, and administering said chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.
- B.19 Method B or B.1-B.18, wherein administering said bipolar trans carotenoid is administering 1.5 mg/kg TSC 45-60 minutes prior administering said chemotherapy, and administering said chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.
- B.20 Method B or B.1-B.19, wherein said cancer is a solid tumor.
- B.21 Method B or B.1-B.20, wherein the cancer is selected from the group consisting of squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer, urological and male genital cancer, bladder cancer, prostate cancer, bone

cancer, cancers of the endocrine glands (e.g., pancreatic cancer), cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer.

- B.22 Method B or B.1-B.21, wherein the cancer is pancreatic cancer.
- B.23 Method B or B.1-B.22, wherein the bipolar trans carotenoid salt is TSC is in the form of a lyophilized composition with a cyclodextrin.
- B.24 Method B or B.1-B.23, wherein the bipolar trans carotenoid is synthetic TSC.
- B.25 Method B or B.1-B.24, wherein the absorbency of the bipolar trans carotenoid salt (i.e., TSC) at a highest peak occurring in the visible light wavelength range (i.e., between 380 to 470 nm) divided by the absorbency of a peak occurring in the ultraviolet wavelength range (i.e., between 220 to 300 nm) is greater than 7, greater than 7.5, greater than 8.0, or greater than 8.5.
- B.26 Method B.25, wherein the quotient obtained is between 7.5 and 9.0.
- B.27 Method B.26, wherein the quotient obtained is between 8.0 and 8.8.

**[0089]** In another embodiment, provided is a method (Method C) of preventing or treating stroke in a mammal (e.g. human) comprising administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

wherein said bipolar trans carotenoid salt is administered at a dose effective to treat stroke.

**[0090]** Further provided is Method C as follows:

- C.1 Method C, wherein the bipolar trans carotenoid is TSC.
- C.2 Method C or C.1, wherein the bipolar trans carotenoid is administered at a dose of 0.05-0.5 mg/kg.
- C.3 Method C or C.1-C.2, wherein the bipolar trans carotenoid is administered at a dose of 0.15-0.35 mg/kg.
- C.4 Method C or C.1-C.3, wherein the bipolar trans carotenoid is administered at a dose of 0.25 mg/kg.
- C.5 Method C or C.1-C.4, wherein said stroke is an ischemic stroke or a hemorrhagic stroke.
- C.6 Method C or C.1-C.5, wherein said stroke is an ischemic stroke.
- C.7 Method C or C.1-C.6, wherein said stroke is a hemorrhagic stroke.
- C.8 Method C or C.1-C.7, wherein the bipolar trans carotenoid salt is TSC is in the form of a composition with a cyclodextrin.
- C.9 Method C or C.1-C.8, wherein the bipolar trans carotenoid salt is TSC is in the form of a lyophilized composition with a cyclodextrin.
- C.10 Method C or C.1-C.9, wherein the bipolar trans carotenoid is synthetic TSC.
- C.11 Method C or C.1-C.10, wherein the absorbency of the bipolar trans carotenoid salt (i.e., TSC) at a highest peak occurring in the visible light wavelength range (i.e., between 380 to 470 nm) divided by the absorbency of a peak occurring in the ultraviolet wavelength range (i.e., between 220 to 300 nm) is greater than 7, greater than 7.5, greater than 8.0, or greater than 8.5.
- C.12 Method C or C.1-C.11, wherein the quotient obtained is between 7.5 and 9.0.
- C.13 Method C or C.1-C.12, wherein the quotient obtained is between 8.0 and 8.8.

**[0091]** In another embodiment, provided is a bipolar trans carotenoid salt (as defined in Method A, B or C) for use in treating cancer in a patient receiving radiation therapy and/or chemotherapy, e.g., for use in a method according to any of Methods A, et seq.; Methods B, et seq.; or Methods C, et seq.

[0092] In another embodiment, provided is a use of a bipolar trans carotenoid salt (as defined in Method A, B or C) in the manufacture of a medicament for treating cancer in a patient receiving radiation therapy and/or chemotherapy, e.g., in a method according to any of Methods A, et seq.; Methods B, et seq.; or Methods C, et seq.

[0093] In another embodiment, provided is a pharmaceutical composition comprising an effective amount of a bipolar trans carotenoid salt (as defined in Method A, B or C) for use in treating cancer in a patient receiving radiation therapy and/or chemotherapy, e.g., for use in a method according to any of Methods A, et seq.; Methods B, et seq.; or Methods C, et seq.

\* \* \*

## Compositions

### **Bipolar Trans Carotenoids**

[0094] The subject disclosure relates to trans carotenoids including trans carotenoid diesters, dialcohols, diketones and diacids, bipolar trans carotenoids (BTC), and bipolar trans carotenoid salts (BTCS) compounds and synthesis of such compounds having the structure:



where:

**Y** (which can be the same or different at the two ends) =H or a cation other than H, preferably Na<sup>+</sup> or K<sup>+</sup> or Li<sup>+</sup>. Y is advantageously a monovalent metal ion. Y can also be an organic cation, *e. g.*, R<sub>4</sub>N<sup>+</sup>, R<sub>3</sub>S<sup>+</sup>, where R is H, or C<sub>n</sub>H<sub>2n+1</sub> where n is 1-10, advantageously 1-6. For example, R can be methyl, ethyl, propyl or butyl.

**Z** (which can be the same or different at the two ends)= polar group which is associated with H or the cation. Optionally including the terminal carbon on the carotenoid (or carotenoid related compound), this group can be a carboxyl (COO<sup>-</sup>) group or a CO group (e.g. ester, aldehyde or ketone

group), or a hydroxyl group. This group can also be a sulfate group ( $\text{OSO}_3^-$ ) or a monophosphate group ( $\text{OPO}_3^-$ ), ( $\text{OP}(\text{OH})\text{O}_2^-$ ), a diphosphate group, triphosphate or combinations thereof. This group can also be an ester group of  $\text{COOR}$  where the R is  $\text{C}_n\text{H}_{2n+1}$ .

**TCRO** = trans carotenoid or carotenoid related skeleton (advantageously less than 100 carbons) which is linear, has pendant groups (defined below), and typically comprises “conjugated” or alternating carbon-carbon double and single bonds (in one embodiment, the TCRO is not fully conjugated as in a lycopene). The pendant groups (X) are typically methyl groups but can be other groups as discussed below. In an advantageous embodiment, the units of the skeleton are joined in such a manner that their arrangement is reversed at the center of the molecule. The 4 single bonds that surround a carbon-carbon double bond all lie in the same plane. If the pendant groups are on the same side of the carbon-carbon double bond, the groups are designated as *cis* (also known as “Z”); if they are on the opposite side of the carbon-carbon bond, they are designated as *trans* (also known as “E”). Throughout this case, the isomers will be referred to as *cis* and *trans*.

**[0095]** The compounds of the subject disclosure are *trans*. The *cis* isomer typically is a detriment -- and results in the diffusivity not being increased. The placement of the pendant groups can be symmetric relative to the central point of the molecule or can be asymmetric so that the left side of the molecule does not look the same as the right side of the molecule either in terms of the type of pendant group or their spatial relationship with respect to the center carbon.

**[0096]** The pendant groups X (which can be the same or different) are hydrogen (H) atoms, or a linear or branched hydrocarbon group having 10 or less carbons, advantageously 4 or less, (optionally containing a halogen), or a halogen. X could also be an ester group ( $\text{COO-}$ ) or an ethoxy/methoxy group. Examples of X are a methyl group ( $\text{CH}_3$ ), an ethyl group ( $\text{C}_2\text{H}_5$ ), a phenyl or single aromatic ring structure with or without pendant groups from the ring, a halogen-containing alkyl group (C1-C10) such as  $\text{CH}_2\text{Cl}$ , or a halogen such as Cl or Br or a methoxy

(OCH<sub>3</sub>) or ethoxy (OCH<sub>2</sub>CH<sub>3</sub>). The pendant groups can be the same or different but the pendant groups utilized must maintain the skeleton as linear.

**[0097]** Although many carotenoids exist in nature, carotenoid salts do not. Commonly-owned US Patent 6,060,511 hereby incorporated by reference in its entirety, relates to trans sodium crocetin (TSC). The TSC was made by reacting naturally occurring saffron with sodium hydroxide followed by extractions that selected primarily for the trans isomer.

**[0098]** The presence of the cis and trans isomers of a carotenoid or carotenoid salt can be determined by looking at the ultraviolet-visible spectrum for the carotenoid sample dissolved in an aqueous solution. Given the spectrum, the value of the absorbance of the highest peak which occurs in the visible wave length range of 380 to 470 nm (the number depending on the solvent used and the chain length of the BTC or BTCS. The addition of pendant groups or differing chain lengths will change this peak absorbance but someone skilled in the art will recognize the existence of an absorbance peak in the visible range corresponding to the conjugated backbone structure of these molecules.) is divided by the absorbency of the peak which occurs in the UV wave length range of 220 to 300 nm can be used to determine the purity level of the trans isomer. When the trans carotenoid diester (TCD) or BTCS is dissolved in water, the highest visible wave length range peak will be at between 380 nm to 470 nm (depending on the exact chemical structure, backbone length and pendant groups) and the UV wave length range peak will be between 220 to 300 nm. According to M. Crow and C. Lambert, *Photochemistry and Photobiology*, Vol. 38 (2), 241-243 (1983) hereby incorporated by reference in its entirety, the result of the calculation (in that case crocetin was analyzed) was 3.1, which increased to 6.6 after purification.

**[0099]** Performing the Crow and Lambert analysis, using a cuvette designed for UV and visible wavelength ranges, on the trans sodium salt of crocetin of commonly owned US Patent 6,060,511 (TSC made by reacting naturally occurring saffron with sodium hydroxide followed by extractions which selected primarily for the trans isomer), the value obtained averages about 6.8. Performing that test on the synthetic TSC of the subject disclosure, that ratio is greater than 7.0 (e.g. 7.0 to 8.5, 7.0 to 8.7, or 7.0 to 9.0), advantageously greater than 7.5 (e.g. 7.5-8.5, 7.5 to 8.7, or 7.5 to 9.0), most advantageously greater than 8. The synthesized material is a "purer" or highly purified trans isomer.

**[00100]** Trans sodium crocetinate (TSC) was developed to cause reoxygenation of hypoxic tissues. TSC can be classified as a kosmotrope, compounds which increase the hydrogen bonding among water molecules. This, in turn, causes the water molecules to change from a random arrangement to one which more resembles the structure of crystals. More structure also results in a reduction in the density of water, allowing small molecules like oxygen or glucose to diffuse through the liquid phase more easily. Kosmotropes are also known to result in this structure formation at only certain, discrete concentrations.

\* \* \*

### **Formulation and Administration**

**[00101]** In formulating trans carotenoids including BTCSs such as trans sodium crocetinate (TSC) with other ingredients (excipients), it is advantageous to: improve the solubility (increase the concentration of the active agent (e.g. TSC) in solution), stability, bioavailability and isotonic balance of the BTC, increase the pH of an aqueous solution, and/or increase the osmolality of an aqueous solution. The excipient should act as an additive to prevent self aggregation of monomeric BTC units in solution, or to prevent pre-mature precipitation of BTC. The addition of the excipient should aid in at least one of these aspects. Bipolar trans carotenoid (BTC) molecules can be formulated in a variety of ways. A basic formulation is a mixture of the BTC in sterile water, administered by intravenous injection. This formulation can be modified through the inclusion of various pharmaceutical excipients, including the cyclodextrins. These formulations can also be administered by intravenous injection.

**[00102]** Any of the above described various liquid formulations can be freeze-dried (lyophilized) to form a dry powder with enhanced solubility and stability characteristics. Such powdered forms are then reconstituted for administration. One method is to reconstitute the powder in a liquid such as saline or sterile water for injection and then administer it by intravenous injection. This method can include the use of a multi-compartment syringe containing the powder in one compartment and liquid in the other compartment. Similarly, the product can be bottled in a vial containing a barrier separating the powder from the liquid. Before administration, the barrier is broken and the components mixed before intravenous injection.

**[00103]** In addition to intravenous injection, routes of administration for specially formulated trans carotenoid molecules include intramuscular injection, delivery by inhalation, oral administration and transdermal administration.

### **Cyclodextrins**

**[00104]** In order to administer some pharmaceuticals, it is necessary to add another compound which will aid in increasing the absorption/solubility/concentration of the active pharmaceutical ingredient (API). Such compounds are called excipients, and cyclodextrins are examples of excipients. Cyclodextrins are cyclic carbohydrate chains derived from starch. They differ from one another by the number of glucopyranose units in their structure. The parent cyclodextrins contain six, seven and eight glucopyranose units, and are referred to as alpha, beta and gamma cyclodextrins respectively. Cyclodextrins were first discovered in 1891, and have been used as part of pharmaceutical preparations for several years.

**[00105]** Cyclodextrins are cyclic (alpha-1,4)-linked oligosaccharides of alpha-D-glucopyranose containing a relatively hydrophobic central cavity and hydrophilic outer surface. In the pharmaceutical industry, cyclodextrins have mainly been used as complexing agents to increase the aqueous solubility of poorly water-soluble drugs, and to increase their bioavailability and stability. In addition, cyclodextrins are used to reduce or prevent gastrointestinal or ocular irritation, reduce or eliminate unpleasant smells or tastes, prevent drug-drug or drug-additive interactions, or even to convert oils and liquid drugs into microcrystalline or amorphous powders.

**[00106]** Although the BTC compounds are soluble in water, the use of the cyclodextrins can increase that solubility even more so that a smaller volume of drug solution can be administered for a given dosage.

**[00107]** There are a number of cyclodextrins that can be used with the Compounds of the disclosure. See for example, US Patent 4,727,064, hereby incorporated by reference in its entirety. Advantageous cyclodextrins are gamma-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin, or other cyclodextrins which enhance the solubility of the BTC.

**[00108]** The use of gamma-cyclodextrin with TSC increases the solubility of TSC in water by 3-7 times. Although this is not as large a factor as seen in some other cases for increasing the

solubility of an active agent with a cyclodextrin, it is important in allowing for the parenteral administration of TSC in smaller volume dosages to humans (or animals). The incorporation of the gamma cyclodextrin also allows for TSC to be absorbed into the blood stream when injected intramuscularly. Absorption is quick, and efficacious blood levels of TSC are reached quickly (as shown in rats).

**[00109]** The cyclodextrin formulation can be used with other trans carotenoids and carotenoid salts. The subject disclosure also includes novel compositions of carotenoids which are not salts (e.g. acid forms such as crocetin, crocin or the intermediate compounds noted above) and a cyclodextrin. In other words, trans carotenoids which are not salts can be formulated with a cyclodextrin. Mannitol can be added for osmolality, or the cyclodextrin BTC mixture can be added to isotonic saline (see below).

**[00110]** The amount of the cyclodextran used is that amount which will contain the trans carotenoid but not so much that it will not release the trans carotenoid.

#### **Cyclodextrin-Mannitol**

**[00111]** A trans carotenoid such as TSC can be formulated with a cyclodextrin as noted above and a non-metabolized sugar such as mannitol (e.g. d-mannitol to adjust the osmotic pressure to be the same as that of blood). Solutions containing about 20 mg TSC/ml of solution can be made this way. This solution can be added to isotonic saline or to other solutions in order to dilute it and still maintain the proper osmolality. See Example 12 of US Patent 8,030,350 hereby incorporated by reference in its entirety.

#### **Mannitol/acetic acid**

**[00112]** A BTCS such as TSC can be formulated with mannitol such as d-mannitol, and a mild acid such as acetic acid or citric acid to adjust the pH. The pH of the solution should be around 8 to 8.5. It should be close to being an isotonic solution, and, as such, can be injected directly into the blood stream.

**Water + saline**

[00113] A BTCS such as TSC can be dissolved in water (advantageously injectable sterile water). This solution can then be diluted with water, normal saline, Ringer's lactate or phosphate buffer, and the resulting mixture either infused or injected.

**Buffers**

[00114] A buffer such as glycine or bicarbonate can be added to the formulation at a level of about 50 mM (in the case of glycine) for stability of the BCT such as TSC.

**TSC and Gamma-Cyclodextrin**

[00115] The ratio of TSC to cyclodextrin is based on TSC:cyclodextrin solubility data. For example, 20 mg/ml TSC, 8% gamma cyclodextrin, 50 mM glycine, 2.33% mannitol with pH 8.2 +/- 0.5, or 10 mg/ml TSC and 4% cyclodextrin, or 5 mg/ml and 2 % cyclodextrin. The ratios of these ingredients can be altered somewhat, as is obvious to one skilled in this art.

[00116] Mannitol can be used to adjust osmolality and its concentration varies depending on the concentration of other ingredients. The glycine is held constant. TSC is more stable at higher pHs. pH of around 8.2 +/- 0.5 is required for stability and is physiologically compatible. The use of glycine is compatible with lyophilization. Alternatively, the TSC and cyclodextrin is formulated using a 50 mM bicarbonate or other buffers, in place of the glycine.

**Endotoxin Removal of Gamma-Cyclodextrin**

[00117] Commercially available pharmaceutical grade cyclodextrin has endotoxin levels that are incompatible with intravenous injection. The endotoxin levels must be reduced in order to use the cyclodextrin in a BTC formulation intended for intravenous injection.

**Lyophilization**

[00118] Lyophilization can be used to produce an easily reconstituted injectable solution.

\* \* \*

**Chemotherapy Agents**

**[00119]** It is contemplated that various chemotherapy agents can be used in the presently disclosed treatments and/or combination therapies. Chemotherapy agents are divided into classes. These are sometimes listed as Alkylating Agents including Platinum based compounds, Antimetabolites, Antitumor Antibiotics including Anthracyclines, Topoisomerase Inhibitors, and Anti-microtubule Agents (Mitotic Inhibitors). Other classifications also exist. It is contemplated that any of the following classes may be used together with the present compositions and methods of treatment.


### **Alkylating agents**

**[00120]** Alkylating agents are the oldest group of chemotherapeutics in use today. Originally derived from mustard gas used in World War I, there are now many types of alkylating agents in use.<sup>[1]</sup> They are so named because of their ability to alkylate many molecules, including proteins, RNA and DNA. This ability to bind covalently to DNA via their alkyl group is the primary cause for their anti-cancer effects. DNA is made of two strands and the molecules may either bind twice to one strand of DNA (intra-strand crosslink) or may bind once to both strands (interstrand crosslink). If the cell tries to replicate crosslinked DNA during cell division, or tries to repair it, the DNA strands can break. This leads to a form of programmed cell death called apoptosis. Alkylating agents will work at any point in the cell cycle and thus are known as cell cycle-independent drugs. For this reason, the effect on the cell is dose dependent; the fraction of cells that die is directly proportional to the dose of drug.


**[00121]** The subtypes of alkylating agents are the nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, and non-classical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin. Tetrazines include dacarbazine, mitozolomide and temozolomide. Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. Non-classical alkylating agents include procarbazine and hexamethylmelamine.

**[00122]** Examples of alkylating agents include: altretamine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, lomustine, melphalan, oxaloplatin, temozolomide, and thiotepa.


### Antimetabolites



Deoxycytidine



Gemcitabine



Decitabine

**[00123]** Deoxycytidine (left) and two anti-metabolite drugs (center and right); Gemcitabine and Decitabine. The drugs are very similar but they have subtle differences in their chemical groups.

**[00124]** Anti-metabolites are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are nucleotides; a molecule comprising a nucleobase, a sugar and a phosphate group. The nucleobases are divided into purines (guanine and adenine) and pyrimidines (cytosine, thymine and uracil). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered chemical groups. These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA, DNA damage can occur and programmed cell death (apoptosis) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case S-phase (the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of

the anti-metabolites are the anti-folates, fluoropyrimidines, deoxynucleoside analogues and thiopurines.

**[00125]** The anti-folates include methotrexate and pemetrexed. Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme that regenerates tetrahydrofolate from dihydrofolate. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish. These are required for thymidylate and purine production, which are both essential for DNA synthesis and cell division. Pemetrexed is another anti-metabolite that affects purine and pyrimidine production, and therefore also inhibits DNA synthesis. It primarily inhibits the enzyme thymidylate synthase, but also has effects on DHFR, aminoimidazole carboxamide ribonucleotide formyltransferase and glycinamide ribonucleotide formyltransferase. The fluoropyrimidines include fluorouracil and capecitabine. Fluorouracil is a nucleobase analogue that is metabolised in cells to form at least two active products; 5-fluorouridine monophosphate (FUMP) and 5-fluoro-2'-deoxyuridine 5'-phosphate (fdUMP). FUMP becomes incorporated into RNA and fdUMP inhibits the enzyme thymidylate synthase; both of which lead to cell death. Capecitabine is a prodrug of 5-fluorouracil that is broken down in cells to produce the active drug. The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, Vidaza, fludarabine, nelarabine, cladribine, clofarabine and pentostatin. The thiopurines include thioguanine and mercaptopurine.

**[00126]** Examples of antimetabolites include: 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), capecitabine (Xeloda®), cytarabine (Ara-C®), floxuridine, fludarabine, gemcitabine (Gemzar®), hydroxyurea, methotrexate, and pemetrexed (Alimta®).

### **Anti-microtubule Agents**

**[00127]** Vinca alkaloids prevent the assembly of microtubules, whereas taxanes prevent their disassembly. Both mechanisms cause defective mitosis.

**[00128]** Anti-microtubule agents are plant-derived chemicals that block cell division by preventing microtubule function. Microtubules are an important cellular structure composed of two proteins;  $\alpha$ -tubulin and  $\beta$ -tubulin. They are hollow rod shaped structures that are required for cell division, among other cellular functions. Microtubules are dynamic structures, which means that they are permanently in a state of assembly and disassembly. Vinca alkaloids and taxanes

are the two main groups of anti-microtubule agents, and although both of these groups of drugs cause microtubule dysfunction, their mechanisms of action are completely opposite. The vinca alkaloids prevent the formation of the microtubules, whereas the taxanes prevent the microtubule disassembly. By doing so, they prevent the cancer cells from completing mitosis. Following this, cell cycle arrest occurs, which induces programmed cell death (apoptosis). Also, these drugs can affect blood vessel growth; an essential process that tumours utilise in order to grow specific. They bind to the tubulin molecules in S-phase and prevent proper microtubule formation required for M-phase.

**[00129]** Taxanes are natural and semi-synthetic drugs. The first drug of their class, paclitaxel, was originally extracted from the Pacific Yew tree, *Taxus brevifolia*. This drug and another in this class, docetaxel, are produced semi-synthetically from a chemical found in the bark of another Yew tree; *Taxus baccata*. These drugs promote microtubule stability, preventing their disassembly. Paclitaxel prevents the cell cycle at the boundary of G2-M, whereas docetaxel exerts its effect during S-phase. Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.

**[00130]** Podophyllotoxin is an antineoplastic lignan obtained primarily from the American Mayapple (*Podophyllum peltatum*) and Himalayan Mayapple (*Podophyllum hexandrum* or *Podophyllum emodi*). It has anti-microtubule activity, and its mechanism is similar to that of vinca alkaloids in that they bind to tubulin, inhibiting microtubule formation. Podophyllotoxin is used to produce two other drugs with different mechanisms of action: etoposide and teniposide.

**[00131]** Examples of mitotic inhibitors include: docetaxel, estramustine, ixabepilone, paclitaxel, vinblastine, vincristine, and vinorelbine.

### **Topoisomerase Inhibitors**

**[00132]** Topoisomerase inhibitors are drugs that affect the activity of two enzymes: topoisomerase I and topoisomerase II. When the DNA double-strand helix is unwound, during DNA replication or transcription, for example, the adjacent unopened DNA winds tighter (supercoils), like opening the middle of a twisted rope. The stress caused by this effect is in part aided by the topoisomerase enzymes. They produce single- or double-strand breaks into DNA, reducing the tension in the DNA strand. This allows the normal unwinding of DNA to occur

during replication or transcription. Inhibition of topoisomerase I or II interferes with both of these processes.

**[00133]** Two topoisomerase I inhibitors, irinotecan and topotecan, are semi-synthetically derived from camptothecin, which is obtained from the Chinese ornamental tree *Camptotheca acuminata*. Drugs that target topoisomerase II can be divided into two groups. The topoisomerase II poisons cause increased levels enzymes bound to DNA. This prevents DNA replication and transcription, causes DNA strand breaks, and leads to programmed cell death (apoptosis). These agents include etoposide, doxorubicin, mitoxantrone and teniposide. The second group, catalytic inhibitors, are drugs that block the activity of topoisomerase II, and therefore prevent DNA synthesis and translation because the DNA cannot unwind properly. This group includes novobiocin, merbarone, and aclarubicin, which also have other significant mechanisms of action.

**[00134]** Topoisomerase inhibitors are grouped according to which type of enzyme they affect:

**[00135]** Topoisomerase I inhibitors include: topotecan, and irinotecan (CPT-11).

**[00136]** Topoisomerase II inhibitors include: etoposide (VP-16), teniposide, and mitoxantrone (also acts as an anti-tumor antibiotic).

### **Cytotoxic Antibiotics**

**[00137]** The cytotoxic antibiotics are a varied group of drugs that have various mechanisms of action. The group includes the anthracyclines and other drugs including actinomycin, bleomycin, plicamycin, and mitomycin. Doxorubicin and daunorubicin were the first two anthracyclines, and were obtained from the bacterium *Streptomyces peucetius*. Derivatives of these compounds include epirubicin and idarubicin. Other clinically used drugs in the anthracycline group are pirarubicin, aclarubicin, and mitoxantrone. The mechanisms of anthracyclines include DNA intercalation (molecules insert between the two strands of DNA), generation of highly reactive free radicals that damage intercellular molecules and topoisomerase inhibition. Actinomycin is a complex molecule that intercalates DNA and prevents RNA synthesis. Bleomycin, a glycopeptide isolated from *Streptomyces verticillus*, also intercalates DNA, but produces free radicals that damage DNA. This occurs when bleomycin binds to a

metal ion, becomes chemically reduced and reacts with oxygen. Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA.

**[00138]** Anthracyclines: Anthracyclines are anti-tumor antibiotics that interfere with enzymes involved in copying DNA during the cell cycle. (Enzymes are proteins that start, help, or speed up the rate of chemical reactions in cells.) They are widely used for a variety of cancers.

**[00139]** Examples of anthracyclines include: daunorubicin, doxorubicin (Adriamycin®), epirubicin, and idarubicin.

**[00140]** A major concern when giving these drugs is that they can permanently damage the heart if given in high doses. For this reason, lifetime dose limits are often placed on these drugs.

**[00141]** Anti-tumor antibiotics that are not anthracyclines include: actinomycin-D, bleomycin, mitomycin-C, and mitoxantrone (also acts as a topoisomerase II inhibitor, see below).

### **Other Drugs**

**[00142]** In another embodiment, one or more benzo[c]chromen-6-one derivative such as SG-529, is administered prior to, during, or after radiation therapy and/or chemotherapy. See US patent 8,475,776 hereby incorporated by reference in its entirety.

\* \* \*

### **Radiation Therapy**

**[00143]** It is contemplated that radiation therapy may be used together with a bipolar trans carotenoid salt (e.g., TSC) in the treatment of a tumor or cancer. The following is a brief description of types of radiation therapy that may be used with the disclosed compositions and in the disclosed methods of treatment.

### **External-beam radiation therapy**

**[00144]** This is the most common type of radiation treatment. It delivers radiation from a machine located outside the body. It can treat large areas of the body, if needed. The machine used to create the radiation beam is called a linear accelerator or linac. Computers with special software adjust the size and shape of the beam. They also direct the beam to target the tumor while avoiding the healthy tissue near the cancer cells. External-beam radiation therapy does not make you radioactive.

**[00145]** Types of external-beam radiation therapy include:

- Three-dimensional conformal radiation therapy (3D-CRT): As part of this treatment, special computers create detailed three-dimensional pictures of the cancer. This allows the treatment team to aim the radiation more precisely. By doing this, they can use higher doses of radiation while reducing the risk of damaging healthy tissue. Studies have shown that 3D-CRT can lower the risk of side effects. For instance, it can limit the damage to the salivary glands, which can cause dry mouth when people with head and neck cancer have radiation therapy.
- Intensity modulated radiation therapy (IMRT): This treatment directs the radiation dose at the tumor better than 3D-CRT by varying the intensity of the beam. IMRT protects healthy tissues from radiation better than 3D-CRT.
- Proton beam therapy: This treatment uses protons, rather than x-rays, to treat some cancers. Protons are parts of atoms that at high energy can destroy cancer cells. Directing protons at a tumor decreases the amount of radiation sent to nearby healthy tissue, reducing damage to this tissue. Because this therapy is relatively new and requires special equipment, it is not available at every medical center. The potential benefits of proton therapy compared to IMRT have not been established for some cancers, such as prostate cancer.
- Stereotactic radiation therapy: This treatment delivers a large, precise radiation dose to a small tumor area. Because of the precision involved in this type of treatment, the patient must remain very still. Head frames or individual body molds are used to limit movement. Although this therapy is often given as a single treatment, some patients may need several radiation treatments.

## **Internal radiation therapy**

**[00146]** This type of radiation treatment is also known as brachytherapy. Radioactive material is placed into the cancer itself or into the tissue surrounding it. These implants may be permanent or temporary and may require a hospital stay. Permanent implants are tiny steel seeds about the size of a grain of rice that contain radioactive material. These capsules are placed inside the body at the tumor site. The seeds deliver most of the radiation around the area of the implant. However, some radiation can be released from the patient's body. This means the patient should take precautions to protect others from radiation exposure while the seeds are active. Over time, the implant loses its radioactivity, but the inactive seeds remain in the body.

## **Methods of Treatment**

### **Cancer**

**[00147]** The subject disclosure relates to the treatment of various tumors and/or cancers (i.e., glioblastoma, pancreatic cancer, etc.). It is well established that tumors are hypoxic with many tumor types being highly hypoxic. Further, it is known that hypoxic tumors are more resistant to radiotherapy and chemotherapy. Through HIF1alpha up-regulation, hypoxia is associated with multiple negative effects that lead to aggressive tumor phenotypes. These effects include increased angiogenesis, increased metastasis, as well as increased resistance to chemotherapy and radiation therapy. Hypoxia via HIF1a affects many genes involved in cancer progression. Bipolar trans carotenoids such as TSC alter expression of HIF1 targeted genes in hypoxic conditions. For example, studies have shown that the VEGF A gene which is upregulated with hypoxia is down regulated with TSC.

**[00148]** The methods of the subject disclosure are directed to administering a dose of a bipolar trans carotenoid such as TSC, at a dose and at the proper time prior to administration of chemotherapy or radiation therapy (as discussed above) such that the oxygen partial pressure is elevated inside the tumor while the chemotherapy or radiation therapy is administered so as to obtain maximum increased killing effect of the chemotherapy and or radiotherapy on the cancer cells/tumor. The administration of the bipolar trans carotenoid, due to its hypoxia reducing

ability, can also decrease angiogenesis, decrease metastasis, and down regulate HIF1a production in the tumor.

**[00149]** Chemotherapy (chemo) uses anti-cancer drugs injected into a vein or taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making this treatment useful for cancers that have spread beyond the organ in which they started.

- Chemotherapy can be given before surgery (sometimes along with radiation) to shrink the tumor. This is known as *neoadjuvant* treatment.
- Chemotherapy can be used after surgery (sometimes along with radiation) to try to kill any cancer cells that have been left behind (but can't be seen). This type of treatment, called *adjuvant* treatment, lowers the chance that the cancer will come back later.
- Chemotherapy is commonly used when the cancer is advanced and can't be removed completely with surgery.

**[00150]** When chemotherapy is given along with radiation, it is known as chemoradiation or chemoradiotherapy. It can improve the effectiveness of the radiation, but it also may cause more severe side effects.

**[00151]** Doctors give chemotherapy in cycles, with each period of treatment followed by a rest period to allow the body time to recover. Each chemotherapy cycle typically lasts for a few weeks.

**[00152]** With bipolar trans carotenoids such as TSC, there are discrete concentrations that produce efficacy in causing maximum oxygen partial pressure in animals or humans. It has been found for all animals tested (including humans), that two such efficacious dosages exist: a "low dose" and a "high dose." For humans, a low dose of 0.15- 0.35 mg/kg, e.g. 0.25 mg/kg, produces the maximum reoxygenation of hypoxic tissue 50 minutes after injection, a change that lasts for a short time, while a high dose of 0.75-2.0 mg/kg, e.g. 1.5 mg/kg, produces the same maximum change but which lasts for over an hour. Increasing the oxygen levels in the cancerous tissue while administering chemotherapy or radiotherapy results in superior cancerous tissue (tumor) killing.

**[00153]** In addition to enhancing the cytotoxicity of chemotherapeutic agents in a tumor, administration of a bipolar trans carotenoid such as TSC can reduce or treat the neurotoxicity or neuropathy that the chemotherapy agents can cause.

### **Pancreatic Cancer**

**[00154]** The various types of pancreatic cancer are discussed earlier in this specification. Chemotherapy can be used at any stage of these pancreatic cancers.

**[00155]** Pancreatic tumors are usually highly hypoxic. Hypoxia results in impairment of the tumor response to chemotherapy agents including antimetabolites such as gemcitabine.

**[00156]** Many different chemo drugs can be used to treat pancreatic cancer, including: gemcitabine (Gemzar®), 5-fluorouracil (5-FU), irinotecan (Camptosar®), oxaliplatin (Eloxatin®), albumin-bound paclitaxel (nab-paclitaxel) (Abraxane®), capecitabine (Xeloda®), cisplatin, paclitaxel (Taxol®), docetaxel (Taxotere®), and irinotecan liposome (Onivyde®).

**[00157]** In people who are healthy enough, 2 or more drugs are usually given together. The current standard of care for patients with metastatic pancreatic cancer includes gemcitabine combined with either erlotinib or nab-paclitaxel. Erlotinib is approved for the treatment of metastatic non-small cell lung cancer and metastatic pancreatic cancer. Nab-paclitaxel is approved for the treatment of breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer.

**[00158]** Other examples of combo therapies are gemcitabine and capecitabine (Xeloda), or gemcitabine, irinotecan, and celecoxib (an arthritis drug). Another combo regimen is the Folfirinox (leucovorin + 5-fluorouracil + oxaliplatin + irinotecan) regimen.

**[00159]** For people who are not healthy enough for combined treatments, a single drug (usually gemcitabine, 5-FU, or capecitabine) can be used.

**[00160]** Advantageous treatment of such tumors includes administration of a high dose – 0.75 – 2.0 mg/kg - of a bipolar trans carotenoid such as TSC, 1-2 hr. prior to administration of one or more chemotherapy agents. A typical cycle would be administration of TSC and the chemotherapy agent (e.g. gemcitabine), or agents (gemcitabine followed directly by nab-paclitaxel), once per week for 3 weeks followed by a week of rest. This cycle can be repeated the following month or months.

**[00161]** In an advantageous embodiment where two chemotherapy agents (nab-paclitaxel and gemcitabine) are given sequentially, TSC (1.5 mg/kg) is given IV as a bolus 45-60 minutes before beginning infusion of 125 mg/m<sup>2</sup> nab-paclitaxel (30-40 min). The IV infusion of 1000 mg/m<sup>2</sup> gemcitabine (30-40 min.) starts soon after the IV infusion of nab-paclitaxel. For example, once per week for three weeks, TSC is administered IV bolus 60 minutes before start of the IV infusion of the nab-paclitaxel, and 90 minutes prior to the start of the IV infusion of the gemcitabine (allotting 30 minutes for administration of each of the chemotherapeutic agents). The effect of the TSC (increasing the oxygen partial pressure in the tumor) will then last for the duration of both chemotherapy drugs. The 3 weeks of the administration above is followed by a week of rest.

**[00162]** Radiation therapy utilizing the 0.15 – 0.35 mg/kg dose of TSC prior to administration of the RT can also be used in the treatment of pancreatic cancer.

### **Glioblastoma Multiforme**

**[00163]** Glioblastoma tumors are highly hypoxic. TSC can be used to enhance the effects of both the radiation therapy (RT) and chemotherapy (e.g. alkylating agent or antimetabolite such as temozolomide (TMZ)). Advantageous treatment of GBM tumors includes administration of a bipolar trans carotenoid such as TSC at a dose of 0.15 – 0.35 mg/kg, prior to, advantageously 45-60 min. prior to, administration of radiotherapy (optionally a chemotherapy agent such as temozolomide is administered, usually the night preceding RT). The TMZ is typically administered daily for the duration of the RT sessions. The bipolar trans carotenoid, e.g. TSC, dosage during radiation therapy is advantageously 0.25 mg/kg given 45 minutes before radiation.

**[00164]** The bipolar trans carotenoid, e.g. TSC dosage during chemotherapy (without radiation) is advantageously 1.5 mg/kg given 1-2 hrs. before the chemotherapeutic agent. For temozolomide administration (5 daily administrations during the monthly week of chemotherapy), the bipolar trans carotenoid is typically administered 2-5 times (advantageously 3 times) during the monthly week. The monthly bipolar trans carotenoid and chemo cycle can continue for 6 or more months.

**[00165]** In an advantageous embodiment, after surgery to remove that portion of the GBM tumor feasibly removed, a bipolar trans carotenoid such as TSC is infused at a dose of 0.25 mg/kg. 45-60 minutes prior to radiation therapy-- (2 Gy) 5 days a week for 6 weeks. Temozolomide is administered (e.g. 75 mg/m<sup>2</sup> temozolomide) per day 7 days per week for the duration of RT. The TSC treatment occurs 3 times per week for the six weeks. After a rest period of 1-4 weeks, for another 6 month period, the TSC is injected at a dose of 1.5 mg/kg 1-2 hr. prior to chemotherapy (e.g. temozolomide 150-200 mg/m<sup>2</sup> on 5 consecutive days for the first week of the month). This TSC administration occurs 3 times per week for the first week of the month for the following 6 months. For a 6-week radiation therapy regimen followed by a 6-month chemotherapy regimen, this results in 36 doses of TSC – 18 during radiation/chemotherapy (6 weeks), and 18 during chemotherapy (6 months).

### **Brain Metastases**

**[00166]** Treatment for brain metastases involves both controlling the symptoms associated with the condition as well as attacking the cancer directly. Brain metastases typically result in edema that can be controlled with the use of steroids; however, long-term use of steroids typically results in side effects that greatly diminishes a patient's quality of life. Approximately 25-45% of patients will experience seizures and require the use anti-epileptic drugs. Surgery is only utilized in patients with a solitary brain metastatic lesion. Radiation therapy remains the standard of care for the vast majority of patients with brain metastases.

**[00167]** Brain metastases are typically hypoxic. Radiation therapy remains the standard of care for the vast majority of patients with brain metastases. Advantageous treatment of such tumors includes administration of a bipolar trans carotenoid such as TSC at a dose of 0.15 – 0.35 mg/kg, e.g. 0.25 mg/kg, 45-60 minutes prior to administration of radiotherapy. In another embodiment, the methods described above for GBM, i.e. use of a chemo agent as well as radiation therapy, are also applicable to treatment of brain metastases.

### **Other Cancers**

**[00168]** Other cancers that can be treated according to the methods of the subject disclosure include solid tumors such as squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer, urological and male genital cancer, bladder cancer, prostate cancer, bone cancer, cancers of the endocrine glands (e.g., pancreatic cancer), cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer.

**[00169]** Advantageous modes of treating the above cancers include the standard of care for a given cancer indication supplemented by administration of a bipolar trans carotenoid such as TSC at a dose of 0.75 – 2.0 mg/kg, e.g. 1.5 mg/kg, prior to administration of chemotherapy, and 0.15- 0.35 mg/kg, e.g. 0.25 mg/kg, of TSC prior to administration of radiotherapy.

#### **Non-Cancer Uses**

**[00170]** It has also been determined that several non-cancer disorders are beneficially treated utilizing an administration regimen of a bipolar trans carotenoid such as TSC, as described below. Pre-clinical efficacy studies using TSC have demonstrated the following:

<u>Species</u>	<u>Condition</u>	<u>Best Dosage</u>
Rat	Hemorrhagic Shock	Low
Rat	Ischemic Stroke	Low
Rat	Hemorrhagic Stroke	Low
Rat	Cancer: Radiation Sensitizer	Low
Rat	Cancer Chemosensitizer	High
Rat	Parkinson's Disease	High
Rat	Memory Recall	High
Mouse	Cancer: Radiation Sensitizer	Low
Mouse	Critical Limb Ischemia	High
Rabbit	Ischemic Stroke	Low

Pig	Hemorrhagic Shock	Low
Pig	Myocardial Infarction	Low
Pig	Wound Healing	High

**[00171]** For humans, TSC at the low dosage e.g. 0.15- 0.35 mg/kg, e.g. 0.25 mg/kg, is administered IV for treating cardiovascular events including stroke, myocardial infarction or hemorrhagic shock (blood loss). See US patent 7,919,527 hereby incorporated by reference in its entirety.

**[00172]** TSC at the high dose 0.75 – 2.0 mg/kg, e.g. 1.5 mg/kg, can act as a neuroprotective agent for humans for treating CNS conditions (Alzheimer's, Parkinson's, memory loss), as well as for promoting wound healing and alleviating extreme limb ischemia. See US patents 7,759,506 and 8,293,804 each of which is hereby incorporated in its entirety. Advantageous administration is orally, 2-5 times per week at a dose that achieves TSC levels equivalent to 0.75 - 2 mg/kg given IV. See commonly owned USP 8,974,822 hereby incorporated by reference in its entirety.

\* \* \* \*

**[00173]** The following Examples are illustrative, but not limiting of the compounds, compositions and methods of the present disclosure. Other suitable modifications and adaptations of a variety of conditions and parameters normally encountered which are obvious to those skilled in the art are within the spirit and scope of this disclosure.

## **EXAMPLES**

### **DMBA Tumors**

**[00174]** Breast tumors were induced through injection of DMBA (dimethylbenzanthracene) under the mammary tissue of female rats. The tumors usually grow in most rats and reach measurable conditions after 10 days.

[00175] The following studies used a method in which a 3-mL syringe is filled first with 1 ml of DMBA dissolved in sunflower seed oil (20 mg DMBA per mL of solution). Following that, 2 mL's of air are pulled into the syringe. The needle of the syringe is then inserted under the mammary tissue near a hind leg and the air in the syringe is carefully injected. The injection of the air forms a "pocket", and then the 1 mL of DMBA solution is injected into that pocket.

[00176] After the tumors have grown up (about 10 days), their volumes are estimated by measuring the diameter (d) and the length (L) of the football-shaped tumors formed. This is done using calipers after feeling the tumor with one's fingers. To estimate the volume of the tumor, you multiply the diameter squared times the length and divide by 2:

$$\text{Tumor volume (in mm}^3\text{)} = \{(d \text{ in mm})^2/2\} \times (L \text{ in mm})$$

[00177] TSC or saline (controls) was injected in the tail vein of the rats at a volume of 0.1 mL and a dose of 0.25 mg/kg TSC about 1-2 hours before the chemotherapeutic agent was injected intraperitoneally (IP) in the rats.

.....

### **Example 1: Platinum-Containing Compounds (Cisplatin)**

[00178] In order to understand which dosages are efficacious when used with chemotherapy, a rat model of breast tumors was used. The model involves injecting the chemical dimethylbenzanthracene (DMBA) under the mammary gland of a female Sprague-Dawley rat. After a few days, tumors begin to grow and can be measured by feeling the football-shaped tumor under the skin and measured using calipers.

[00179] In this study, a platinum based compound was used (cisplatin). The low dose (for rats) 0.1 mg/kg of TSC given (IV) 50 minutes before chemotherapy was not effective in the

study, but the high dose (for rats) 0.25 mg/kg of TSC given 2 hours before chemotherapy was efficacious as shown in the figure below.

**[00180]** High Dose of TSC given 2 hours before 1 mg/kg cisplatin. Cisplatin (1 mg/kg) was injected IP on days 0, 4, 11, 18. As shown in Fig. 2, rats treated with high dose TSC and cisplatin showed significant improvement in tumor volume over the control.

### **Example 2 Antimetabolites (Gemcitabine)**

**[00181]** In this study, the antimetabolite (gemcitabine) was used. The low dose of TSC given 50 minutes before chemotherapy was not effective in the study, but the high dose of TSC given 2 hours before chemotherapy was efficacious as shown in Fig. 3. The concentrations of the low dose TSC and the high dose TSC are the same as those defined in Example 1.

**[00182]** High Dose of TSC given 2 hours before 10 mg/kg gemcitabine. Gemcitabine (10 mg/kg) was injected IP on days 0, 3. As shown in Fig. 3, rats treated with high dose TSC and gemcitabine showed a significant decrease in tumor volume on day 3. For comparison, rats in the control group showed only a marginal increase in tumor volume. Most rats in both groups were dead on Day 6. Gemcitabine dose was cut in half, and the same behavior was seen.

**[00183]** High dose of TSC given 2 hours before 5mg/kg gemcitabine. Gemcitabine (5 mg/kg) was injected IP on days 0, 3: Most rats in both groups were dead on Day 7. Results are shown in Fig. 4. Rats given high dose TSC and gemcitabine showed substantially less tumor growth than those in the control group. Note that % tumor growth for both groups is greater than for gemcitabine dosage of 10 mg/kg.

**[00184]** Time of TSC injection relative to that of the chemotherapy agent was tried with a gemcitabine dose of 7.5 mg/kg, but data obtained only for Day 2 after injection of gemcitabine because of its toxicity in rats. Dosing 2 hours before the chemotherapy is best although all methods reduced tumor growth relative to control.

**[00185]** High dose of TSC given 2 hours before 7.5 mg/kg gemcitabine. TSC high dose given i) concurrently, ii) 1 hour before, and iii) 2 hours before gemcitabine (7.5 mg/kg, given IV). As shown in Fig. 5, timing of TSC administration 2 hours prior to chemotherapeutic agent gives best results in all studies.

### **Example 3 Alkylating Agents (Temozolomide)**

[00186] A high dose of TSC as defined in Example 1 was given 2 hours prior to chemotherapy with temozolomide. Results are summarized in Fig. 6. Note that pseudoprogession was seen in this study, which accounts for the increase in tumor volume in subjects administered TSC together with temozolomide on day 7. Pseudoprogession is also seen in human chemotherapy of glioblastoma when using temozolomide as a radio- and chemo-sensitizer.

#### **Example 4 Anti-tumor Antibiotics - Anthracyclines (Doxorubicin)**

[00187] A high dose of TSC as defined in Example 1 was given 2 hours prior to chemotherapy with doxorubicin. Pseudoprogession was also seen in this study, which accounts for the increase in tumor volume in subjects administered TSC together with doxorubicin on day 7. The results, summarized in Fig. 7, show a marked reduction in tumor growth in comparison with the control group.

#### **Example 5 Mitotic Inhibitors-Taxanes (Paclitaxel)**

[00188] A high dose of TSC as defined in Example 1 was given 2 hrs. prior to chemotherapy with paclitaxel. Doses of chemotherapy and TSC were given on Days 0, 4, 8, 14. Pseudoprogession was also seen in this study. The results, summarized in Fig. 8, show a marked reduction in tumor growth in comparison with the control group.

#### **Example 6 Trans Sodium Crocetinate Phase 1/2 Clinical Trial in GBM**

[00189] To date, TSC has been used in 148 human subjects in Phase 1 and Phase 2 clinical trials, with no serious adverse events reported. A Phase 1/2 clinical trial was recently completed examining TSC in patients with GBM. The Phase 1/2 clinical trial in GBM enrolled 59 patients with newly diagnosed disease that received TSC in conjunction with radiation therapy (RT) and temozolomide (TMZ). In the Phase I portion of the trial TSC was initially administered three times per week at half-dose to three patients prior to radiation. Six additional patients received

full dose TSC for six weeks in combination with radiation. No dose-limiting toxicities were identified in the nine patients during the Phase I portion of the trial. Fifty additional patients were enrolled in the Phase II trial at full dose TSC in combination with TMZ and RT. Four weeks after completion of RT, all patients resumed TMZ for five days every four weeks, but no further TSC was administered.

**[00190]** More specifically, fifty-nine patients with newly-diagnosed GBM were enrolled. Patients received standard of care (SOC) radiation therapy (RT) (2 Gy/day, 5 days/week for 6 weeks) and TMZ (75 mg/m<sup>2</sup>) starting within 5 weeks after a surgical resection of their tumor, if such surgery were possible. Patients receiving only needle biopsies (i.e., no surgery) were also enrolled.

**[00191]** In addition to the SOC, TSC was administered 3 times per week, 0.25 mg/kg IV, usually on Monday, Wednesday and Friday, about 45 minutes prior to the RT sessions.

**[00192]** Four weeks after completion of RT, patients began chemotherapy with TMZ for 5 days of the first week of a 4 week cycle. This continued for 6 such cycles. No TSC was administered during this chemotherapy.

Overall Survival

**[00193]** Using the values reported for certain time points in the SOC analysis (Stupp R, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996, 2005), as shown in Table 2 below, it was determined that survival was 10% greater in the TSC trial (i.e., the present study) at both 1 and 2 years than the rate in the historical trial, which had established the SOC for GBM in 2005.

Table 2: Overall Survival from Kaplan-Meier Analysis

Time	Observed Survival Rate with TSC Treatment	Historical Survival Rate (from Stupp study)
1 year	71.2%	61.1%
2 years	36.3%	26.5%

**[00194]** Both the 1- and 2-year survivals in the current trial fall outside the Stupp confidence intervals for those time points, suggesting statistical differences. That is, one can be

95% confident that survival in the present trial is statistically different from that which established the SOC.

**[00195]** Previous studies have shown that survival can be positively correlated with the extent of the initial resection, which means that those patients having inoperable tumors have a lower probability of survival. The current trial incorporating TSC into the SOC RT and TMZ for GBM enrolled essentially equal numbers of patients who had undergone complete resection (14) and no resection (15). These patients comprised approximately 50% of the 59 patients enrolled in the trial. The other 50% were patients who had undergone partial resection.

**[00196]** It would be expected that the patients who have complete resections would have higher survivability rates than those solely having needle biopsies (i.e., partial resections). However, contrary to this expectation, survival at 2 years was quite similar for both groups in the present trial. In the subgroup of patients considered inoperable, the chance of survival at two years for those who received TSC was increased by over 100%, as 40% in the TSC group were alive at two years compared to less than 20 percent in the control. For comparison, survivability of the biopsy-only patients was observed to be 42.9% at two years. All groups of patients administered TSC in addition to SOC treatment showed better survival at 2 years than the overall survival rate seen with the historical controls.

#### Tumor Sizes

**[00197]** One particularly unexpected result of the present study was the effect that the treatment had on reduction in tumor sizes. In the trials, 56 patients received full-dose TSC therapy. Of those patients, 4 did not live long enough to have an MRI study after baseline, 1 patient was censored, and 14 patients underwent complete resections. Thus, 37 patients had either partial resection or no resection (biopsy only) and their tumors could be followed over time. Fig. 9 illustrates the observed tumor area changes in these 37 tumor-bearing patients (shown as overall tumor volume of all patients). As shown in Fig. 10, the vast majority of these 37 patients showed reduction in tumor size, with almost 20% of the full-dose patients showing complete elimination of tumors, which emphasizes the beneficial use of TSC for this indication. This effect has not been documented in humans in the art.

**[00198]** Thus, it is shown that TSC is effective on glioblastoma multiforme tumors when given at a low dose (0.25 mg/kg) 45 minutes before radiation was administered.

\* \* \*

**[00199]** It will be readily apparent to those skilled in the art that the numerous modifications and additions can be made to both the present compounds and compositions, and the related methods without departing from the disclosed methods and compositions.

What is claimed is:

1. A method of treating cancer in a mammal comprising
  - a) administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen,

- b) administering to the mammal radiation therapy, wherein said bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.
2. A method as in claim 1, wherein the bipolar trans carotenoid is TSC administered at a dose of 0.15-0.35 mg/kg 45-60 minutes prior to administration of said radiation therapy.
3. A method as in claims 1 or 2, wherein the bipolar trans carotenoid is TSC administered at a dose of 0.25 mg/kg.
4. A method as in any preceding claim, wherein said radiation therapy is external beam radiation therapy.
5. A method as in any preceding claim, wherein said radiation therapy is administered 5 times per week for 6 weeks.
6. A method as in any preceding claim, further comprising administering chemotherapy to said mammal.

7. A method as in claim 6, wherein said administering chemotherapy is administering temozolomide 7 times per week for 6 weeks.
8. A method as in claims 6 or 7, wherein said chemotherapy is administered after said radiation therapy.
9. A method as in any preceding claim, wherein said cancer is brain cancer.
10. A method as in claim 9, wherein said brain cancer is a glioblastoma multiforme.
11. A method of treating cancer in a mammal comprising
  - a) administering to the mammal a bipolar trans carotenoid salt having the formula:



where:

Y = a cation which can be the same or different,

Z = a polar group which can be the same or different and which is associated with the cation, and

TCRO = a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, and

- b) administering chemotherapy to the mammal, wherein said bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said chemotherapy.
12. A method as in claim 11, wherein the bipolar trans carotenoid is TSC administered at a dose of 0.75 – 2.0 mg/kg 1-2 hours prior to administration of said chemotherapy.
13. A method as in any of claims 11-12, wherein said cancer is a solid tumor.
14. A method as in any of claims 11-13, wherein the cancer is selected from the group consisting of squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer,

- urological and male genital cancer, bladder cancer, prostate cancer, bone cancer, cancers of the endocrine glands (e.g., pancreatic cancer), cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer.
15. A method as in any of claim 11-14, wherein the cancer is pancreatic cancer.
  16. A method as in any of claims 11-15, wherein said chemotherapy is selected from the group consisting of alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, and anti-microtubule agents.
  17. A method as in any of claims 11-16, wherein said chemotherapy is one or more compounds selected from the group consisting of temozolomide, gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.
  18. A method as in any of claims 11-17, wherein said chemotherapy is one or more compounds selected from gemcitabine, irinotecan, and celecoxib.
  19. A method as in any of claims 11-18, wherein said chemotherapy is one or both of gemcitabine and nab-paclitaxel.
  20. A method as in any of claims 11-19, wherein said chemotherapy is gemcitabine.
  21. A method as in any of claims 11-20, wherein administering said bipolar trans carotenoid is administering 1.5 mg/kg TSC 45-60 minutes prior administering said chemotherapy, and administering said chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.
  22. A method as in any of claims of claims 11-19, wherein administering said bipolar trans carotenoid is administering 1.5 mg/kg TSC 45-60 minutes prior administering said chemotherapy, and administering said chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.
  23. A method as in any preceding claim wherein the bipolar trans carotenoid salt is TSC is in the form of a composition with a cyclodextrin.

24. A method as in any preceding claim wherein the bipolar trans carotenoid salt is TSC is in the form of a lyophilized composition with a cyclodextrin.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 17/23844

A. CLASSIFICATION OF SUBJECT MATTER  
IPC(8) - A61K 41/00, A61K 31/11 (2017.01)  
CPC - A61K 31/11, A61K 45/06, A61K 9/19, A61K 31/202

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2006/0194973 A1 (Gainer et al.) 31 August 2006 (31.08.2006); p41, para[0003], para[0097], para[0102], para[0103], para[0348], para[0349]	1-3, 11-13
A	WO 2011/152869 A1 (Diffusion Pharmaceuticals Llc) 08 December 2011 (08.12.2011); entire document	1-3, 11-13
A	US 2011/0196038 A1 (Gainer et al.) 11 August 2011 (11.08.2011); entire document	1-3, 11-13
A	US 2006/0276372 A1 (Lockwood et al.) 07 December 2006 (07.12.2006); entire document	1-3, 11-13
A	WO 2004/011423 A3 (Hawaii Biotech Inc) 06 May 2004 (06.05.2004); entire document	1-3, 11-13

Further documents are listed in the continuation of Box C.  See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 19 May 2017	Date of mailing of the international search report <b>03 JUL 2017</b>
--	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer: Lee W. Young  PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/23844

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
- 2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
- 3.  Claims Nos.: 4-10, 14-24  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

- 1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
- 4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.